UNSPSC 51413908: Nesapidil

This classification denotes a vasodilating agent with the molecular formula C23H28N4O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QRY8KPT3QI, chemically known as (rs)-1-(4-(2-methoxyphenyl)-1-piperazinyl)-3-(3-(5-methyl-1,3,4-oxadiazol-2-yl)phenoxy)-2-propanol but generally known as nesapidil, which bears US NIH Compound Identifier 175512. European Medicines Agency schedules Nesapidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09207MIG.

UNSPSC 51413908 Nesapidil (Commodity) covers emergency and specialty pharmaceutical products supplied to state and local health agencies, fire rescue services, and multi-state purchasing cooperatives. State and local governments procure individual medications and pharmaceutical line items through this code—recent solicitations show purchases of specific injectable medications such as Labetalol, Epinephrine, Adenosine, and Diltiazem for emergency medical use, as well as generic multi-source pharmaceuticals and over-the-counter products through cooperative purchasing agreements. Issuing bodies include municipal fire rescue departments, state health and human services commissions, and multi-state cooperative purchasing alliances administering contracts on behalf of participating state and local facilities. The code reflects a mix of direct municipal procurement and coordinated multi-jurisdictional purchasing vehicles.

The City of Tampa's Purchasing Department solicited Advanced Life Support Medications (IFB 26P00188, due April 8, 2026) for Tampa Fire Rescue in Hillsborough County, Florida, requesting 370 units of Labetalol HCI 100mg vials, 1,810 units of Epinephrine 1:10,000 injections, 330 units of Adenosine 6mg vials, and 1,020 units of Diltiazem 25mg vials, with an estimated contract value of $40,000 and a Small Local Business Enterprise (SLBE) sheltered market designation offering a 5 percent bid discount. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP (S1070000015802, due March 26, 2026) for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local facilities including Oregon, requiring vendor pricing for identified pharmaceutical products with specific National Drug Codes and compliance with Good Manufacturing Practices and the Drug Supply Chain Security Act. The Texas Health and Human Services Commission issued an RFI (HHS0017013, due April 3, 2026) to gather vendor capabilities on implementing a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. Recent activity spans Florida, Texas, Minnesota, and Oregon.